Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) will have a stand #2349 at the BIO International Convention (Philadelphia, June 3-6, 2019).
More info..

Medical technology company Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) has signed the first licence agreement for its world-leading PromarkerD predictive test for diabetic kidney disease in the United States.
More info..

Medical technology company Proteomics International Laboratories Ltd (Proteomics International;
ASX: PIQ) has announced the official product launch of its world leading predictive diagnostic test for diabetic kidney disease, "PromarkerD".
More info..

MedTech pioneer Proteomics International (PILL; ASX: PIQ) has entered into a strategic alliance with CPR Pharma Services (CPR), targeting the high growth area of clinical trials and related research, with an offer to acquire 10% of CPR's share capital through the issue of 4 million PIQ shares.
More info..

Proteomics International Laboratories Ltd (ASX: PIQ) (PILL) announced today results from its validation clinical study showing that the PromarkerD blood test can predict the onset of diabetic kidney disease better than any current measure.
More info..

Proteomics International Laboratories Ltd (PILL; ASX:PIQ) is the leader in predictive diagnostics for diabetic kidney disease, according to an independent Frost & Sullivan report released this month.
More info..

Proteomics International Laboratories Ltd (PILL; ASX:PIQ) is the leader in predictive diagnostics for diabetic kidney disease, according to an independent Frost & Sullivan report released this month.
More info..

Proteomics International Laboratories Ltd ('PILL'; ASX: PIQ), a world leader in biomarker discovery in multiple project areas, will advance deals in Singapore, Hong Kong and Shanghai this week for the commercialization of PromarkerD, its ground-breaking predictive test, in Asia Pacific markets.
More info..